Saturday, May 17, 2025
wellness India Expo
Home Tags Panacea Biotec

Tag: Panacea Biotec

FACE TO FACE: Davender Kumar Bhati, Co Founder & Director, Invigorate...

In an exclusive rapid-fire interview on the sidelines of Global Bio India 2024 in New Delhi, Davender Kumar Bhati, Co-Founder & Director, Invigorate Biotechnologies shared insights on his company’s key R&D focus areas, startup ecosystem, government policies and much more.

India’s first Indigenous dengue vaccine ‘DengiAll’ enters Phase 3 clinical trials

ICMR and Panacea Biotec begin large-scale testing of DengiAll, marking a major step towards combating dengue in India

Panacea Biotec donates 125,000 doses of Easyfive-TT to Cuba

This donation will allow the continuation of the cycle of vaccination for children foreseen within the national immunization program carried out by the Ministry of Public Health of Cuba

Panacea Biotec bags US $127.30 million for supply of pentavalent vaccine

UNICEF award is worth US $98.755 million for supply of around 99.70 million doses during calendar years 2023-2027

Sputnik V could accelerate the vaccination drive in India

With more people coming forward to get vaccinated, the Russian vaccine could help in sharing the load, writes Prof. Ashok Rattan, Advisor, PathKind Labs.....................

Panacea Biotec to produce 100 million doses of Sputnik V annually

The first batch of Russia's COVID-19 vaccine produced at Panacea Biotec’s facilities in Baddi will be shipped to the Gamaleya Center for quality control.................

Sputnik V vaccine authorized in India

India has become the 60th country to approve the Russian vaccine, Sputnik V, one of only three vaccines registered so far in the country.........................

Panacea Biotec to produce 100 million doses of Sputnik V vaccine

The move is expected to facilitate the global supply of Sputnik V vaccine to international partners of the Russian Direct Investment Fund (RDIF).................................

Panacea Biotec gets INR 992 crore funding boost by IndiaRF

Investment to be used for one-time settlement with existing lenders, working capital and growth requirements

Panacea Biotec gets USFDA’s nod for its generic breast cancer drug

The company is looking ahead at commercializing the what it calls the best product in the United States and several other markets worldwide in collaboration with Apotex.............